POLQ and cancer: In this study, we address these compelling scientific and experimental challenges using our bespoke telomere fusion sequencing capacity (52,66) in association with whole genome sequencing (WGS) in two independent wild-type (WT) and POLQ-deficient human cancer cell lines transiting telomere-driven crisis.